SLG
NBRV

Stanley-Laman Group’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Stanley-Laman Group’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-103
Closed -$154K – 294
2017
Q4 		$154K Buy
+103
New +$163K 0.03% 263

Other funds holding NBRV

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Stanley-Laman Group's NBRV Position: Q1 2018 in Review

Stanley-Laman Group sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2018, closing a stake of 103 shares — an estimated $154K sold.

Stanley-Laman Group first reported a position in NBRV in Q4 2017 and held it in 1 quarter. The position peaked at $154K in Q4 2017. 46 funds tracked by Wall St. Rank hold NBRV as of Q1 2018.

  • Stanley-Laman Group reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 103 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2018, an estimated $154K.
  • Stanley-Laman Group first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 1 quarter.
  • Stanley-Laman Group's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $154K in Q4 2017.
  • 46 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2018.

Based on Stanley-Laman Group's 13F filing for Q1 2018, filed 1 May 2018.